Drug
anti-PD-1/PD-L1
anti-PD-1/PD-L1 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Other(2)
Detailed Status
unknown2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 21 (100.0%)
Trials by Status
active_not_recruiting133%
unknown267%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_2
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
NCT05605496
unknown
Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma
NCT05701553
unknown
Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC
NCT04943679
Clinical Trials (3)
Showing 3 of 3 trials
NCT05605496Phase 2
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
NCT05701553
Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma
NCT04943679
Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3